The potential issues with Zantac just became a little more complicated. Zantac is the brand name of a common heartburn medication called ranitidine. As we have reported, there have been multiple, and ongoing, recalls of ranitidine after testing of lots of the drug showed unacceptable levels of the probable human carcinogen N-nitrosodimethylamine (NDMA).

Initially, it was thought that the ranitidine/NDMA connection was related to similar recalls of the popular blood pressure medications Valsartan, Losartan, and Irbesartan. However, based upon recent testing by a popular independent laboratory and resulting petition filed with the Federal Drug Administration (FDA), there are now claims that ranitidine, itself, causes high levels of NDMA exposure in patients. Essentially, the claims are that the unstable ranitidine molecule breaks down under certain conditions, including those in the human digestive tract, to create harmful levels of NDMA. Thus, significant NDMA exposure would result from taking brand name or generic ranitidine, regardless of where it was manufactured.

This type of NDMA exposure has been linked to various cancers, including:

  • Stomach
  • Small intestine
  • Colorectal
  • Esophageal
  • Liver
  • Bladder

And, in more limited circumstances:

  • Prostate
  • Pancreatic
  • Leukemia
  • Non-Hodgkin’s Lymphoma
  • Multiple Myeloma
  • Kidney

So far, testing of alternatives to ranitidine, such as Pepcid, Tagamet, Nexium, Prevacid, and Prilosec, do not show the same NDMA exposure potentials.

As always, please feel free to contact Stark & Stark to speak with one of or attorneys, free of charge, who can help assess any defective drug or medical device claims that you may have.

Photo of Martin P. Schrama Martin P. Schrama

Martin P. Schrama is an expert Civil Trial Attorney as certified by the Supreme Court of New Jersey. He is also the Chair and Co-Founder of the Stark & Stark Mass Tort Litigation practice, as well as a member of the firm’s Commercial…

Martin P. Schrama is an expert Civil Trial Attorney as certified by the Supreme Court of New Jersey. He is also the Chair and Co-Founder of the Stark & Stark Mass Tort Litigation practice, as well as a member of the firm’s Commercial Litigation and Intellectual Property practices.

Photo of Stefanie Colella-Walsh Stefanie Colella-Walsh

Stefanie Colella-Walsh is a Shareholder and member of Stark & Stark’s Litigation, Insurance Coverage & Liability, Intellectual Property and Mass Torts Groups where she concentrates her practice in complex litigation with a focus in mass tort and pharmaceutical litigation. She is currently involved…

Stefanie Colella-Walsh is a Shareholder and member of Stark & Stark’s Litigation, Insurance Coverage & Liability, Intellectual Property and Mass Torts Groups where she concentrates her practice in complex litigation with a focus in mass tort and pharmaceutical litigation. She is currently involved in representing numerous plaintiffs in federal and state environmental and pharmaceutical mass tort cases, as well as state and federal class action litigations based upon commercial, employment, civil rights, investments/securities and consumer fraud claims. Ms. Colella-Walsh frequently writes about timely legal and legislative developments impacting plaintiffs in mass tort and product liability actions for Stark & Stark’s Mass Tort Law Blog.